BACKGROUND: Parkinson's disease (PD) is a leading cause of death and disability worldwide, and is associated with a significant Global Burden of Disease (GBD). We analyzed the trends in PD incidence, mortality, and disability-adjusted life year (DALY) burden in China, and compared them with global data. METHODS: Estimates and 95% uncertainty intervals (UIs) for incidence, mortality, DALYs, years lived with disability (YLDs), and years of life lost (YLLs) for PD were extracted from the GBD, Injuries, and Risk Factors Study 2021. We describe the epidemiology of PD at global and Chinese levels, analyze trends in incidence and mortality from 1990 to 2021 by joinpoint regression models, and decompose PD burden according to population size, age structure, and epidemiological changes. RESULTS: GBD 2021 estimated 508,378 (95% UI: 430,499-592,748) incident cases of PD, 92,035 (95% UI: 75,908-108,133) deaths, and 2,159,514 (95% UI: 1,826,196-2,521,344) DALYs in China, with the higher age-standardized rate (ASR) in incidence, mortality and DALYs than the global levels. The DALY burden of PD in China increased slightly from 1990 to 2021, consistent with the global upward trend. Joinpoint regression analysis indicated that the ASR of incidence in China increased faster than the global average, while the ASR of mortality decreased, with the fastest decline in 2004-2014. Decomposition analysis revealed that men and the middle sociodemographic index (SDI) quintile (32.82%) were responsible for the most significant DALYs, whose changes were primarily driven by population growth and aging. CONCLUSIONS The burden of PD showed an overall increasing trend from 1990 to 2021, which was primarily driven by population growth and aging. This study highlights the significant challenges in controlling and managing PD, including the increase in cases and gender differences, which may provide guidance for comprehensive strategies to address the changing profiles of PD in China.
Humans ; Parkinson Disease/mortality* ; China/epidemiology* ; Global Burden of Disease ; Male ; Incidence ; Female ; Disability-Adjusted Life Years ; Middle Aged ; Aged ; Adult ; Quality-Adjusted Life Years ; Aged, 80 and over ; Cost of Illness ; Adolescent ; Pattern Analysis, Machine

Objective:To analyze the non-motor symptom characteristics of patients with different subtypes of progressive supranuclear palsy (PSP).Methods:Demographic data were collected from patients diagnosed with probable or possible PSP in the PSP cohort at Qilu Hospital of Shandong University from June 2019 to June 2023. Motor symptoms were evaluated using the Progressive Supranuclear Palsy Rating Scale (PSPRS), Unified Parkinson′s Disease Rating Scale-Ⅲ , and the Freezing of Gait Questionnaire. Non-motor symptoms were assessed using the Non-Motor Symptoms Scale (NMSS), the Montreal Cognitive Assessment, the Hamilton Depression Rating Scale, and the Hamilton Anxiety Rating Scale. Patients were grouped into PSP with Richardson syndrome (PSP-RS), PSP with Parkinsonism (PSP-P), PSP with progressive gait freezing (PSP-PGF), and other subtypes (PSP-other) based on clinical classification. The study compared the non-motor symptom characteristics among the 4 groups and used linear regression models to evaluate the influencing factors of PSP non-motor symptoms.Results:A total of 153 PSP patients were included in this study, with a male-to-female ratio of 89∶64 and an age of (66.0±6.6) years. Among them, 83 were in the PSP-RS group (54.2%), 32 in the PSP-P group (20.9%), 27 in the PSP-PGF group (17.6%), and 11 in the PSP-other group (7.2%). The total NMSS score for non-motor symptoms in PSP patients was 62.6±38.5, with 8.8±4.7 non-motor symptoms per patient. The most common non-motor symptoms among all PSP patients were sleep/fatigue [130/153 (85.0%)], gastrointestinal symptoms [129/153 (84.3%)], urinary symptoms [113/153 (73.9%)], attention/memory impairment [112/153 (73.2%)], and mood symptoms [108/153 (70.6%)]. The total NMSS score of the PSP-RS group (70.8±36.0) was higher than that of the PSP-PGF group (49.4±40.3; t=2.561, P=0.011). The number of non-motor symptoms in the PSP-RS group (9.9±4.4) was greater than that in the PSP-P group (7.7±5.5; t=2.365, P=0.019) and the PSP-PGF group (6.9±4.3; t=2.978, P=0.003). The incidence of memory decline in the PSP-RS group [52/83 (62.7%)] was higher than that in the PSP-P group [10/32 (31.3%); χ 2=9.165, Bonferroni-corrected P=0.012], and the incidence of constipation in the PSP-RS group [49/83 (59.0%)] was higher than that in the PSP-PGF group [8/27 (29.6%); χ 2=7.056, Bonferroni-corrected P=0.048]. Multivariate regression analysis showed that the bulbar symptom score ( β=5.591, 95% CI 1.792-9.389, P=0.005), limb motor score ( β=1.786, 95% CI 0.398-3.174, P=0.013), and gait/axial score ( β=1.956, 95% CI 0.149-3.763, P=0.036) in PSPRS were all associated with non-motor symptom scores. Conclusions:Different PSP subtypes exhibit distinct non-motor symptom profiles. PSP-RS patients bear a heavier non-motor symptom burden, with higher incidences of memory decline and constipation than other subtypes. These findings may aid in the early recognition and clinical diagnosis of PSP.

Objective:To analyze the non-motor symptom characteristics of patients with different subtypes of progressive supranuclear palsy (PSP).Methods:Demographic data were collected from patients diagnosed with probable or possible PSP in the PSP cohort at Qilu Hospital of Shandong University from June 2019 to June 2023. Motor symptoms were evaluated using the Progressive Supranuclear Palsy Rating Scale (PSPRS), Unified Parkinson′s Disease Rating Scale-Ⅲ , and the Freezing of Gait Questionnaire. Non-motor symptoms were assessed using the Non-Motor Symptoms Scale (NMSS), the Montreal Cognitive Assessment, the Hamilton Depression Rating Scale, and the Hamilton Anxiety Rating Scale. Patients were grouped into PSP with Richardson syndrome (PSP-RS), PSP with Parkinsonism (PSP-P), PSP with progressive gait freezing (PSP-PGF), and other subtypes (PSP-other) based on clinical classification. The study compared the non-motor symptom characteristics among the 4 groups and used linear regression models to evaluate the influencing factors of PSP non-motor symptoms.Results:A total of 153 PSP patients were included in this study, with a male-to-female ratio of 89∶64 and an age of (66.0±6.6) years. Among them, 83 were in the PSP-RS group (54.2%), 32 in the PSP-P group (20.9%), 27 in the PSP-PGF group (17.6%), and 11 in the PSP-other group (7.2%). The total NMSS score for non-motor symptoms in PSP patients was 62.6±38.5, with 8.8±4.7 non-motor symptoms per patient. The most common non-motor symptoms among all PSP patients were sleep/fatigue [130/153 (85.0%)], gastrointestinal symptoms [129/153 (84.3%)], urinary symptoms [113/153 (73.9%)], attention/memory impairment [112/153 (73.2%)], and mood symptoms [108/153 (70.6%)]. The total NMSS score of the PSP-RS group (70.8±36.0) was higher than that of the PSP-PGF group (49.4±40.3; t=2.561, P=0.011). The number of non-motor symptoms in the PSP-RS group (9.9±4.4) was greater than that in the PSP-P group (7.7±5.5; t=2.365, P=0.019) and the PSP-PGF group (6.9±4.3; t=2.978, P=0.003). The incidence of memory decline in the PSP-RS group [52/83 (62.7%)] was higher than that in the PSP-P group [10/32 (31.3%); χ 2=9.165, Bonferroni-corrected P=0.012], and the incidence of constipation in the PSP-RS group [49/83 (59.0%)] was higher than that in the PSP-PGF group [8/27 (29.6%); χ 2=7.056, Bonferroni-corrected P=0.048]. Multivariate regression analysis showed that the bulbar symptom score ( β=5.591, 95% CI 1.792-9.389, P=0.005), limb motor score ( β=1.786, 95% CI 0.398-3.174, P=0.013), and gait/axial score ( β=1.956, 95% CI 0.149-3.763, P=0.036) in PSPRS were all associated with non-motor symptom scores. Conclusions:Different PSP subtypes exhibit distinct non-motor symptom profiles. PSP-RS patients bear a heavier non-motor symptom burden, with higher incidences of memory decline and constipation than other subtypes. These findings may aid in the early recognition and clinical diagnosis of PSP.

Parkinson′s disease is a common clinical degenerative disease of the nervous system, and rapid eye movement sleep behavior disorder (RBD) is a common sleep symptom of patients with Parkinson′s disease. This article reviews the pathogenesis, epidemiology, clinical characteristics, imaging manifestations, clinical evaluation and treatment of RBD in patients with Parkinson′s disease, in order to deepen the understanding of RBD in patients with Parkinson′s disease.

OBJECTIVETo study and establish the optimal technology for the preparation of evodiae juice.

METHODThe contents of evodiamine, rutaecarpine and evodin were simultaneously determined with HPLC, and each yield of the three compounds were chosen as the evaluating indicator. The orthogonal test coupled with the weighted coefficient method were adopted to acquire the optimal technology for the preparation of evodiae juice.

RESULTThe study showed that the optimal technology for the preparation of evodiae juice was as follows: decocted three times while the first time was with 12-fold of water socked 30 minutes and decocted 45 minutes, the second time was with 8-fold of water decocted 20 minutes and the third time was with 6-fold of water decocted 20 minutes.

CONCLUSIONThis method is simple and accurate. The optimal technology is suitable for industry manufacture of evodiae juice.

Drugs, Chinese Herbal ; analysis ; Evodia ; chemistry ; Technology, Pharmaceutical ; methods